Kornimate/medical-research-clean huggingface dataset:
modification of chronic inflammation by inhaled carbon monoxide in patients with stable chronic obstructive pulmonary disease (copd)

Conditions: Pulmonary Disease, Chronic Obstructive

Summary: the purpose of this study is to determine whether carbon monoxide is effective in the treatment of stable copd.

copd is characterised by a chronic pulmonary inflammation and a shifted oxidant/antioxidant balance. the main cause of this inflammation is smoking. after smoking cessation, this inflammation and shifted oxidant/antioxidant balance continues. this causes an increased deterioration of lung function compared to healthy persons of matching age. the ongoing inflammation appears to be relatively insensitive to corticosteroid therapy. until now, there is no therapy for this inflammation. both in vitro and in vivo studies show that carbon monoxide has, besides an antioxidant capacity, anti-inflammatory properties. the aim of this trial is to study whether the inflammation can be reduced by inhalation of carbon monoxide.

Eligibility criteria:
inclusion criteria: * men and women, age \> 40 years. women must be post-menopausal (i.e. at least one year must have passed after the last menstruation), surgically sterile or using acceptable contraceptives, as judged by the investigator. * a diagnosis of copd according to the criteria of the american thoracic society (ats); a disease state characterised by the presence of chronic airway obstruction due to chronic bronchitis (cough/sputum on most days a week for 3 months a year for at least two successive years); or emphysema. * fev1 \> 0.7 litres * fev1/fvc ratio \< 70% (equation retrieval system \[ers\] equations) * a smoking history of \> 10 pack years * completely stopped smoking \> 1 year ago * no upper or lower respiratory tract infection in the last 4 weeks * in a stable phase of copd, as judged by the investigator * signed and dated informed consent obtained before any study related procedures (including withdrawal of concomitant medication) are conducted exclusion criteria: * treatment with immune-modulating agents for any other disease * history of asthma; former diagnosis of asthma * arterial oxygen tension (pao2) \< 8.0 kpa * any significant other pulmonary disease or disorder (e.g. alpha1-antitrypsin deficiency, bronchiectasies), as judged by the investigator * patients with other significant disease or disorder (like cardiovascular, gastrointestinal, liver, renal, neurological, musculoskeletal, endocrine, metabolic \[including diagnosed diabetes\], malignant, psychiatric, major physical impairment), which, in the opinion of the investigator may either put the patient at risk because of participation in the study; or may influence the results of the study, or the patient's ability to participate in the study. * patients unable to blow reproducable lung function measurements * patients using medicine with anti-oxidant character like n-acetyl-cysteine.

Keywords: carbon monoxide copd inflammation sputum induction stable copd
her2 and la/muc: a multi-country chart review cohort study

Conditions: Urothelial Carcinoma

Summary: this study is being done to learn about urothelial cancers that make her2 and how that affects treatment choices for participants with urothelial cancer. during this study, the medical and health records of participants will be reviewed to learn more about their health. participants will have urothelial cancer that has grown in the body near where it started (locally advanced) and cannot be removed (unresectable) or has spread through the body (metastatic).


Eligibility criteria:
inclusion criteria: * histologically confirmed uc originating from the renal pelvis, ureters, bladder, or urethra. mixed-cell type tumors are eligible as long as urothelial cell carcinoma is the predominant cell type. * locally advanced unresectable or metastatic stage disease * formalin fixed paraffin embedded (ffpe) tumor tissue blocks (or freshly sectioned slides, see laboratory manual for details) available for her2 testing. * at least 1 prior line of systemic therapy for locally advanced unresectable or metastatic urothelial carcinoma (la/muc), including 1 line of platinum-containing chemotherapy. * initiation of anticancer therapy for uc after prior progression on platinum-based therapy with or without maintenance avelumab between 01 january 2019 and 12 months before the end of data collection * radiographically documented and measurable disease progression immediately before index date exclusion criteria: * any concurrent malignant neoplasm requiring systemic therapy during the study window * enrollment in a therapeutic clinical trial and received non-standard of care treatment during index line of therapy

Keywords: urothelial cancer bladder cancer her2 mutations her2 overexpression her2 amplification seattle genetics
family cohort study on primary osteoporosis

Conditions: Family Genetic Characteristics of Osteoporosis

Summary: bone metabolism and genetic characteristics of osteoporosis pedigree with kidney-yang deficiency

families with or without osteoporosis of kidney-yang deficiency type will be included and compared with each other. their genetic characteristics, bone changes, and tcm constitution are the focus of research.

Eligibility criteria:
inclusion criteria: * be able to cooperate with inspection.there is blood relationship between the members of the enrolled family. exclusion criteria: * unable to cooperate with inspection.there is not blood relationship between the members of the enrolled family.

Keywords: osteoporosis families kidney-yang deficiency genetic correlation of disease bone density
protect and connect: couple hiv prevention for drug involved male offenders

Conditions: Sexually Transmitted Diseases; Unsafe Sex; Substance-Related Disorders

Summary: this study is a randomized controlled trial (rct) that will rigorously evaluate the implementation, effectiveness and cost-effectiveness of a couple-based integrated human immunodeficiency virus (hiv) and drug abuse prevention intervention (connect ii) with drug-involved male offenders charged with misdemeanors and their primary female sexual partners, implemented by frontline providers in criminal court, community court or probation (ccp) sites in nyc, compared to ccp standard treatment of care services (tau). the primary outcomes are to reduce sexually transmitted infections (stis) and increase condom use.

hiv/acquired immune deficiency syndrome (aids) and criminal justice involvement are critical intersecting public health issues for drug-involved men. low income, black and hispanic men especially bear the burden of the hiv epidemic and are over-represented in the u.s. criminal justice system. recent centers for disease control and prevention (cdc) surveillance data suggest that the health disparity in hiv rates is actually increasing for black men: current estimates suggest 1 in 16 black men in the u.s. will be infected with hiv in their life time. these hiv/sti transmission risks are fueled by high rates of poverty, incarceration, unemployment, and lack of access to health care and prevention services. the proposed study thus targets an underserved population at the epicenter of the epidemic in the u.s.

Eligibility criteria:
inclusion criteria: * couples * both partners are aged 18 or older * identify each other as their primary sexual partner of opposite sex * relationship has existed at least 3 months * at least one partner reports having unprotected vaginal or anal intercourse with the other partner in the past 90 days * at least one partner reports exposure to an outside hiv risk in the past year * male partner reports and is verified by court records of being charged with a misdemeanor * male partner is currently under court supervision or probation exclusion criteria: * either partner shows evidence of significant psychiatric or could impairment as confirmed by the macarthur competence assessment tool during the screening eligibility interview. * either partner reports severe physical or sexual violence perpetrated by the other partner in the past year as measured on the revised conflict tactics scale * either partner is unable to commit to participate in the study through to completion * either partner reports that the couple is planning a pregnancy within the next 12 months * either partner is not fluent in english as determined during informed consent

Keywords: sti sexually transmitted infection hiv criminal justice probation couples drug use
surveillance of zika-related microcephaly in sub-saharan africa and asia

Conditions: Microcephaly; Congenital Infection

Summary: this study will explore whether zikv is currently responsible for neurological complications, and particularly microcephaly, in aedes-infested regions of sub-saharan africa (ssa) and asia. this will inform regional public health strategies, such as vaccination of women of child-bearing age. it will also demonstrate the public health impact of zikv infection and increase the understanding of other regional infectious (e.g. cytomegalovirus) causes of microcephaly.

this study will last for 2 years, and will include only new cases of microcephaly. surveillance will take place in large maternities in urban areas (standard procedure) * in each city, \~3000 live births per month will be monitored, so that on average one microcephaly will be diagnosed per month per city (i.e., 24 per city in 2 years) * microcephaly is defined as less than -3 standard deviation (sd), according to the intergrowth standards by age and sex with abnormal ultrasound and/or clinical examination. data collection (study activity) * a questionnaire with demographic, exposure and pregnancy details for all mothers clinical exam and laboratory testing (standard procedure and study activity) * various biological samples (e.g. blood, placenta) will be collected from mothers and newborns/fetuses and tested for presence of zikv, and for other infectious (e.g. rubella, cytomegalovirus) causes of microcephaly * physical, neurological, hearing and visual examinations for all live births will be performed where possible. analysis and reporting (study activity) o all results will be shared publically through conferences and peer-reviewed publications.

Eligibility criteria:
inclusion criteria: * all infants or fetuses with microcephaly, (defined as head circumference ≤-3sd according to intergrowth standards for gestational age and sex, detected during the mother's pregnancy, or at the end of the mother's pregnancy at one of the participating maternities) * and with abnormal ultrasound and/or clinical examination findings for newborns. exclusion criteria: * infants/fetuses with microcephaly whose mothers are under the age of 18 years, * or inability or refusal of mothers/ guardians to give informed consent.
masseter muscle thickness in gasser ganglion radiofrequency treatment

Conditions: Trigeminal Neuralgia; Gasserian Ganglion; Lesion

Summary: trigeminal neuralgia is common painful disorder in pain medicine clinics. gasserian ganglion radiofrequency thermocoagulation is one of the treatment option in patients with trigeminal neuralgia in refractory cases. the most commonly involved branch in trigeminal neuralgia is the mandibular branch. masseter muscle is innervated by mandibulary nerve branch of the trigeminal nerve. the radiofrequency thermocoagulation therapy is used to ablate the affected trigeminal nerve branch and some of patients complain of subjective masseter weakness after this procedure. in theoretical basis, muscles innervated by target nerve are affected from ablation procedure. in this study the primary aim is to evaluate the change of the masseter muscle thickness in patients treated by gasserian ganglion radiofrequency thermocoagulation. the results may also show possible functional effect of the procedure related with masseter muscle.


Eligibility criteria:
inclusion criteria: * pain refractory to medical therapy for at least 3 months * planning radiofrequency thermocoagulation of gasserian ganglion * accept ultrasound measurements to be performed exclusion criteria: * refused to participate in the study * not attending follow-ups regularly * coagulation disorder * pregnancy * localized or systemic infection
resistance training in elderly

Conditions: Sarcopenia; Atrophy; Aging

Summary: in the present study the investigators aim to determine whether protein supplementation can augment the response to a 12 week resistance training program in healthy elderly men.


Eligibility criteria:
inclusion criteria: * living independently exclusion criteria: * diabetes * cardiovascular disease * orthopedic limitations * any disorder known to compromise ability for resistance training * history of resistance training in past 5 years

Keywords: resistance training protein supplementation hypertrophy
does erector spinal block improve quality of recovery after laparoscopic cholecystectomy

Conditions: Postoperative Recovery

Summary: the primary aim of this prospective, randomized study is to evaluate the effect of erector spinae block (esp) on quality of recovery with the qor-40 questionnaire in patients undergoing elective laparoscopic cholecystectomy.

laparoscopic cholecystectomy, one of the most common general surgical procedures, is the gold standard for the treatment of symptomatic gallbladder diseases. although it is considered as minimally invasive surgery, pain in the early postoperative period is still meaningful. proper pain control is essential for optimizing clinical outcomes and earlier ambulation after surgery. traditional pain management with opioids provide good pain control, however, have undesirable side effects such as nausea, vomiting, and respiratory depression. multimodal analgesia strategies with different classes of analgesics or local anesthetics may enhance pain relief and reduce side effects after surgery. the esp a newer regional nerve blockade, has been used as part of a multimodal strategy to optimize postoperative pain control. the primary aim of this study is to evaluate the effect of esp block on postoperative recovery quality in patients undergoing laparoscopic cholecystectomy with qor-40 recovery questionnaire. secondary aim is to assess the effect of esp block on postoperative pain, nausea, and vomiting. study hypothesize is that patients who receive an esp block in addition to the current standard of care, consisting of parenteral opioids and paracetamol, will have a clinically significant improvement in their qor-40 at postoperative day 1 and lower pain levels, as measured by nrs in comparison to those patients who receive the current standard of care along.

Eligibility criteria:
inclusion criteria: * american society of anesthesiology (asa) physical status i-ii * scheduled for elective laparoscopic cholecystectomy exclusion criteria: * a history of allergy to local anesthetics * known coagulation disorders * infection near the puncture site * chronic opioid intake * patient with psychiatric disorders * inability to communicate
the effect of nafamostat mesilate in prolonging filter patency with patients on continuous renal replacement therapy

Conditions: Acute Kidney Injury

Summary: continuous renal replacement therapy (crrt) has been considered as an effective modality for renal replacement therapy in hemodynamically unstable patients within intensive care unit (icu) except for the necessity of anticoagulation. the severity and peculiarities of icu patients often make it equivocal to use anticoagulation. this is a prospective randomized controlled study to show the difference in filter life span and adverse event between hf1000 (nafamostat mesilate) group and m100 (heparin-free) group.


Eligibility criteria:
inclusion criteria: * patients who have at least one of the hemorrhagic tendencies of following conditions and needs crrt hemodynamically; 1. platelet count \< 100,000 2. aptt \> 60 sec 3. pt-inr \> 2.0 4. active hemorrhage 5. surgery within 48 hours 6. cerebral hemorrhage within 3 months or history of major bleeding 7. septic shock or dic. exclusion criteria: * pregnancy, breast feeding, possibility of pregnancy, * allergy to nafamostat mesilate, * other conditions that physician consider unfit for candidate.

Keywords: nafamostat mesilate heparin continuous renal replacement therapy
bax 326 pediatric study

Conditions: Hemophilia B

Summary: the purpose of this study is to assess bax 326 pharmacokinetic parameters, to evaluate its hemostatic efficacy, safety, immunogenicity, and changes in health-related quality of life in pediatric patients.

the secondary outcome measure: area under the plasma concentration versus time curve from 0 to 72 hours (h) post-infusion analysis was not done due to the different time-points for the last pk blood sample, auc0-72 h was redundant and only total auc was included in the pk analysis.

Eligibility criteria:
main inclusion criteria: * participant and/or legal representative has/have voluntarily provided signed informed consent * participant has severe (fix level \< 1%) or moderately severe (fix level ≤ 2%) hemophilia b * participant is \< 12 years old at the time of screening * participant has no evidence of a history of fix inhibitors (based on the participant's medical records) * participant is immunocompetent as evidenced by a cd4 count ≥ 200 cells/mm\^3 main exclusion criteria: * participant has a detectable fix inhibitor at screening, with a titer ≥ 0.6 bethesda unit (bu) * participant has a history of allergic reaction, e.g. anaphylaxis, following exposure to fix concentrate(s) * participant has evidence of an ongoing or recent thrombotic disease * participant has an inherited or acquired hemostatic defect other than hemophilia b
determination of the duration of the dual antiplatelet therapy by the degree of the coverage of the struts on optical coherence tomography from the randomized comparison between everolimus-eluting stents(ees) versus biolimus a9-eluting stents(bes)

Conditions: Ischemic Heart Disease

Summary: the purpose of the study is 1\> to compare neointimal stent coverage after oct-guided vs. angio-guided pci, 2\> to compare neointimal stent coverage at 3 months after ees vs bes implantation, 3\> to determine the duration of dual antiplatelet therapy by oct measurement at 3 months


Eligibility criteria:
inclusion criteria: * patients ≥ 20 years old * patients with ischemic heart disease who are considered for coronary revascularization with stent implantation. * significant coronary de novo lesion (stenosis \> 70% by quantitative angiographic analysis) treated by single des ≤ 25mm * reference vessel diameter of 2.5 to 3.5 mm by operator assessment exclusion criteria: * complex lesion morphologies such as aorta-ostial, unprotected left main, chronic total occlusion, graft, thrombosis, and restenosis * reference vessel diameter \ 4.0mm * heavy calcified lesions (definite calcified lesions on angiogram) * primary pci for stemi * contraindication to anti-platelet agents * treated with any des within 3 months at other vessel * creatinine level ≥ 2.0 mg/dl or esrd * severe hepatic dysfunction (3 times normal reference values) * pregnant women or women with potential childbearing * life expectancy \< 1 year
comparison of egoscue versus pilates exercises in patient with mechanical low back pain

Conditions: Low Back Pain

Summary: mechanical low back pain arises intrinsically from the spine, intervertebral disc,or surrounding soft tissues.it is causes by muscular spasm, and other soft tissue injuries. the aim of the study will be to compare the effect of egoscue versus pilates exercises on pain, range of motion and muscle endurance in patient with mechanical low back pain.

a randomized clinical trial will be conducted at riphah clinic lahore through consecutive sampling technique on 30 patients which will be allocated using simple random sampling through sealed opaque enveloped into group a and group b. group a will be treated with pilates exercises at frequency 2 sets 5 repetitions 5 days a week and group b will be treated with egoscue exercises at the frequency of 2 sets with 5 repetitions 5 days a week. outcome measures will be conducted through pain, disability,lumber range of motion, muscle flexibility, extensor muscle endurance, lateral muscle endurance, flexors muscle endurance questionnaires after 4 weeks. data will be analyzed during spss software version 21. after assessing normality of data by anova test, it will be decided either parametric or non-parametric test will be used within a group or between two groups.

Eligibility criteria:
inclusion criteria: * age 18 to 40 years * both gender * patient with non-radiating pain * pain nprs \<7 * positive mcgill extensor endurance test ( \<101 seconds) * positive mcgill lateral flexor endurance test (\<54 sec right side, \<55sec left side) * positive mcgill flexor endurance test \< 120 seconds * positive finger to floor test : \> 48cm in males, \>50cm for females * patient with oswestry disability index (odi) \< 40 odi score * decrease lumbar rom; lateral flexion, extension, flexion exclusion criteria: * sacroiliac joint dysfunction (sijd) * coccydynia * lumber disc pathology * malignancy * recent fractures

Keywords: muscle endurance pain range of motion muscle flexibility
sirolimus+abatacept+mycophenolate mofetil for prophylaxis of agvhd in patients receiving haplo-hsct who are intolerant to calcineurin inhibitors

Conditions: Acute Leukemia; Myelodysplastic Syndromes; Severe Aplastic Anemia

Summary: graft-versus-host disease (gvhd) is an important complication after transplantation, with an incidence of 40-60%, which can increase non-relapse mortality if poorly controlled. at present, the standard prophylaxis for gvhd is cyclosporine combined with methotrexate. however, calcineurin inhibitors (cni) can cause some vital side effects, which are not tolerated by some patients. therefore, this study aims to explore the safety and efficacy of sirolimus in combination with abatacept and mycophenolate mofetil for the prophylaxis of gvhd in patients with haplo-hsct who are intolerant to calcineurin inhibitors.


Eligibility criteria:
inclusion criteria: 1. primary disease: hematological malignancies (including acute leukemia, myelodysplastic syndromes), nonmalignant disorders (including severe aplastic anaemia) 2. contraindication or intolerance to cni 1. glomerular filtration rate (gfr) 60-89 ml/min/1.73m2 before transplantation or allergy to cni 2. intolerance to cni during conditioning or within +45 days post transplantation, such as cni nephrotoxicity (creatinine higher than the upper limit of normal), uncontrolled hypertension, neurological toxicity, or other conditions deemed by physician to be inappropriate for cni 3. receiving haplo-hsct for the first time exclusion criteria: 1. allergy or intolerance to study drugs 2. active infection 3. active gvhd 4. transplantation-associated thrombotic microangiopathy 5. key organ dysfunction: liver injury (total bilirubin more than 2 upper limit of normal) or heart injury (symptomatic heart failure or ejection fraction\<50%) 6. eastern cooperative oncology group (ecog) score \>2 7. expected survival time \<30 days 8. patients could not cooperate

Keywords: abatacept mycophenolate mofetil sirolimus graft-versus-host-disease haploidentical calcineurin inhibitor